Status:
UNKNOWN
Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Lead Sponsor:
Immunicon
Conditions:
Colorectal Cancer
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Brief Summary
This study enrolled patients with measurable metastatic colorectal cancer. Blood was drawn prior to the patient receiving a new therapy for his/her cancer and subsequently at 7-14 days, 3-4 weeks, and...
Eligibility Criteria
Inclusion
- Measurable metastatic carcinoma of the colon or rectum.
- 1st or 2nd line chemotherapy (3rd line acceptable with epidermal growth factor receptor \[EGFR\] targeted therapy)
- Chest/abdomen/pelvis scans every 6-12 weeks
- ECOG 0-2
- Hemoglobin (Hgb) \> or = 8g/dl within 7 days prior to enrollment
- Age \> or = to 18 years of age
Exclusion
- Cumulative weekly blood draws exceeding 150mL/week
- Brain metastasis
- Prior history of other carcinoma within the last 5 years, except ductal carcinoma in situ (DCIS), non-invasive cervical cancer or non-melanoma skin cancer
- Surgery within 14 days of the initial blood draw, excluding surgical placement of a central venous device
Key Trial Info
Start Date :
March 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
486 Patients enrolled
Trial Details
Trial ID
NCT00133913
Start Date
March 1 2004
End Date
January 1 2009
Last Update
March 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111